Research Article | Open Access
Parvez Anwar Khan1 , Nazish Fatima1, Haris Manzoor Khan1, Midhat Ali Khan1, Asim Azhar2 and Sanjay Sharma1
1Department of Microbiology, Jawaharlal Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh – 202 002, Uttar Pradesh, India.
2Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh – 202 002, Uttar Pradesh, India.
J Pure Appl Microbiol. 2021;15(3):1230-1235 | Article Number: 6968 | © The Author(s). 2021
Received: 05/04/2021 | Accepted: 22/06/2021 | Published: 28/06/2021

Candidiasis is recognized as a significant cause of morbidity, especially in immunocompromised individuals. An epidemiologic change in Candida species and emergence of resistance can impact the usage of antifungal agents as empirical therapy for Candidiasis in patients with or without AIDS. The present study was done to find out: i) The species of Candida isolated from H.I.V. and Non-HIV infected patients. ii) The resistance pattern of these Candida isolates to antifungal agents. A total of 160 Candida species isolates (80 isolates each from H.I.V. and Non-HIV infected patients) were characterized. Identification of yeast isolates was made by standard procedures including morphology (Staib agar, cornmeal agar, CHROMagar), germ tube test, fermentation, and assimilation of sugars and growth at 42°C. In addition, sensitivity testing was done using the broth microdilution method (M27-A2) as per the C.L.S.I. guidelines against amphotericin B, nystatin, voriconazole, fluconazole, ketoconazole, and itraconazole. In both the groups, i.e., H.I.V. and Non-HIV infected patients, Candida albicans was the most common species (61.2 % and 85 % respectively), followed by Candida guilliermondi (16.2 % and 5 %), Candida tropicalis (5 % and 3.7 %), Candida krusei (5% and 2.5 %), Candida dubliniensis 1(5 % and 1.2 %) and others. Among HIV infected patients fluconazole resistance was 16.25%, ketoconazole 13.5%, clotrimazole 12.5%, itraconazole 6.25 %. In the non-HIV infected group, fluconazole resistance was 8.75% and itraconazole 1.25%. For the appropriate treatment of Candida infections, antifungal susceptibility has become an essential tool, especially in the present scenario of increasing resistance.


Candida, HIV-Positive, Antifungal, resistance, oral Candidiasis


Candidiasis has been recognized as a significant cause of morbidity, especially in immunocompromised individuals. The use of highly active antiretroviral therapy (HAART) causes inhibition of viral replication, which eventually causes the recovery of CD4 T+ lymphocytes in HIV-positive patients. The prolonged course of H.I.V. infection further puts at risk these patients to repeated episodes of various opportunistic infections like Candidiasis that can increase in severity with the progression of H.I.V. disease. In addition, candidiasis’ management causes the development of antifungal resistance amid the course of treatment1-3. Infection by resistant Candida strains does not respond to antifungal therapy even with standard doses for an appropriate time duration4,5.

Another scenario is that multiple exposures to antifungal agents can cause a shift to Candida species other than albicans, which will eventually lead to hard to treat, refractory, and recurrent infections6,7. Thus, an epidemiologic change in Candida species and the emergence of resistance could cause a significant impact on the use of antifungal agents as empirical therapy for Candidiasis in patients with or without AIDS. Opportunistic infections, including Candidiasis, aggravate morbidity and decrease the span and quality of life of HIV-infected patients and thus require accurate diagnosis and adequate treatment. In-vitro sensitivity testing is clinically helpful in foreseeing whether the patients are going to improve with treatment or not. However, in India, in the same way as other developing nations, in-vitro antifungal testing is not performed as routine testing. Accordingly, not much is known about the in-vitro antifungal sensitivity of Candida species cultured from HIV-infected patients with Candidiasis. This study was done to find out the species of Candida isolated from H.I.V. Negative and H.I.V. Positive patients and their resistance pattern to antifungal agents.

Materials and Methods

Patients and setting
One hundred and sixty patients with Candidiasis (80 each, with and without H.I.V. infection) were included in this study. Cases were enrolled from the outpatient department (O.P.D.), In-patient wards, Anti-Retroviral Treatment clinic, and I.C.T.C. of the Department of Microbiology, J.N.M.C.H., Aligarh Muslim University. A complete physical examination and clinical history were elicited to know any similar disease episodes, use of antifungal drugs, and past medical history. In addition, specimens for mycological investigations were collected based on the system involved, including blood, oral and vaginal swabs, esophageal biopsy, skin scrapping, and feces.

The serostatus (H.I.V.) of the patients was screened and confirmed at H.I.V. Testing Laboratory (I.C.T.C.) as per the recommendation of the National AIDS Control Organization (N.A.C.O.) (Guidelines for H.I.V. testing, March 2018). All tests were performed manually according to the manufacturer’s recommendations. Flow-Cytometry was used for the estimation of the absolute CD4 cell counts of the patients.

Fungal culture and species identification
One Hundred and sixty Candida isolates (80 isolates each from H.I.V. and Non-HIV infected patients) were characterized. Identification of yeast isolates was made by standard procedures including morphology on CHROMagar, Cornmeal agar, and Staib agar (HiMedia® Laboratories Pvt. Ltd, India), germ tube formation, fermentation and assimilation of sugars and growth at 42°C 8.

In vitro antifungal susceptibility testing
The determination of the M.I.C. (minimum inhibitory concentration) was done using a broth microdilution test as per the C.L.S.I. guidelines (Clinical and Laboratory Standard Institute) M27- A3 and M27-S4). The following antifungal agents were used- amphotericin B, nystatin, ketoconazole, fluconazole, itraconazole, and voriconazole (HiMedia® Laboratories Pvt. Ltd, India)9,10. Aliquots of 100 microliters of each antifungal drug at a double concentration of the final concentration were put in the wells of 96-well microtiter plates. Before testing, fungal strains were subcultured and incubated at 30°C for 24 hours. Next, 100 μl of the inoculum was added to each microdilution well containing 100 μl of the serial dilution of the antifungal agents to reach the final concentration; the plates were then incubated at 35°C for 48 hours. The minimum inhibitory concentrations (M.I.C.s) were calculated after 48 hours. American Type Culture Collection (A.T.C.C.) strains recommended by C.L.S.I., C. albicans (ATCC 64550), C. parapsilosis (ATCC 22019), and C. krusei (ATCC 6258) were used as controls.


Demographically, both the groups, ie. H.I.V. Negative and Positive patients presenting with Candidiasis were comparable in terms of age and sex. The HIV-positive patients with Candidiasis constituted 47 (59%) males and 33 (41%) females with a mean age of 32 years. The HIV-negative patients with Candidiasis constituted 41 (51%) males and 39 (49%) females with a mean age of 29 years (Table-1). Heterosexual contact was the most common mode of the transmission of H.I.V. infection (Table-2)

Table (1):
Demographic Profile of Study Groups.

HIV Negative (n=80) HIV Positive
Sex Male 41 47
Female 39 33
Age (Years) Mean (±SD) 29 (±9.31) 32 (±11.26)
Marital status Married 52 39
Unmarried 41 28
Social background Rural 51 35
Urban 42 32
Occupation Farmer 20 19
Driver 00 04
Laborer 10 02
Business 24 11
Army/police 02 00
Others 22 46

Table (2):
Risk profile (mode of transmission of H.I.V. Infection) of H.I.V. positive patients with Candidiasis.

Mode of H.I.V. infection
HIV positive (n=80)
HIV Negative (n=80)
Blood and products
Injection drug user
Not specified

Most of the patients with Candidiasis in the H.I.V. positive group presented with oral Candidiasis (51 patients), followed by vulvovaginal Candidiasis, Cutaneous Candidiasis, oesophageal Candidiasis, candidal diarrhea, and candidemia. In the HIV-negative group, 31 patients presented with oral Candidiasis, and 28 patients were diagnosed with vulvovaginal Candidiasis. In addition, five patients were confirmed with candidemia and were of the pediatric age group (Table 3).

Table (3):
Distribution of Various presentations of Candidiasis in H.I.V. Positive and H.I.V. Negative patients.

HIV positive
HIV Negative (n=80)
Oral Candidiasis only
Vulvovaginal candidiasis
Cutaneous Candidiasis
Esophageal Candidiasis
Candida diarrhea

In H.I.V. Negative patients, Candida albicans was the commonest species isolated (85 %), followed by Candida guilliermondi in 5%, Candida parapsilosis in 2.5 %, Candida tropicalis in 3.7 %, Candida krusei in 2.5 %, and Candida dubliniensis 1.2 % [Table-4].

Table (4):
Distribution of various species of Candida isolated from H.I.V. positive and H.I.V. Negative Patients.

Candida Species
HIV Positive (%)
HIV Negative (%)
Candida albicans
49 (61.2)
68 (85)
Candida guilliermondi
13 (16.2)
4 (5 )
Candida parapsilosi
6 (7.5)
2 (2.5)
Candida tropicalis
4 (5)
3   (3.7)
Candida krusei
4 (5)
2   (2.5)
Candida dubliniensis
4 (5)
1   (1.2)

In HIV-positive patients, Candida albicans was isolated from 61.2 %, followed by Candida guilliermondi (16.2 %), Candida parapsilosis (7.5%) Candida tropicalis (5 %), Candida krusei (5%), and Candida dubliniensis (5 %).

Among HIV infected patients fluconazole resistance was 16.25%, ketoconazole 13.5%, clotrimazole 12.5%, itraconazole 6.25 %. Higher M.I.C. against the azoles was also recorded in many isolates rendering them intermediately sensitive. A significantly higher number of non-albicans Candida isolates were resistant to azoles (6 out of 31). In H.I.V. Negative group fluconazole resistance was found in 8.75% and itraconazole 1.25%. [Table-5].

Table (5):
Sensitivity profile of isolated candida species to various antifungal agents.

Antifungal Resistance
HIV Positive (%)
HIV Negative (%)
13 (16.25)
7 (8.75)
11 (13.5)
6 (7.5)
10 (12.5)
6 (7.5)
5   (6.25)
1 (1.25)
Amphotericin B
0    (0)
0 (0)
2    (2.5)
2 (2.5)

In this study, oropharyngeal Candidiasis was the most common presentation in HIV-positive (63.7%) and HIV-negative patients (38.7%), similar to other studies’ results. Khedri et al1 reported Oropharyngeal Candidiasis as the most common mucocutaneous infection in HIV-positive individuals with an incidence of 59.3%. Shilpa et al. et al.11 documented Candidiasis in 49 % of HIV-positive patients, Nagalingeswaran K et al12 in 70 %, A. Singh et al13 in 65 % and Anupriya Wadhwa et al14 reported Candidiasis in 50% HIV-positive patients. Other studies have documented the prevalence of Candidiasis in 23 to 27% of patients co-infected with H.I.V.15,16.

In 80 cases of Candidiasis who were H.I.V. positive, Candida albicans were isolated from 49 (61.2%) while non- candida albicans, including C. guilliermondi, C. tropicalis, C. parapsilosis, C. dubliniensis, were isolated from 31 (38.7%) patients. Khedri et al.1 reported C. albicans in 52.9% HIV-positive cases with Oropharyngeal Candidiasis. Even Though Candida albicans persists as a significant causative species, the frequency of non-albicans species of Candida has modestly risen. Oral Candidiasis in HIV/AIDS patients caused by non-albicans Candida is well documented14,15,17. A study by Ismail H Sahand et al.17 on the presence of Candida in oral swabs of HIV-infected individuals reports the isolation rate of candida albicans from 52% of patients and non-albicans Candida from the 48%14,17 reported that 40% of all Candida isolates to be Non-albicans14.

Sixteen Percent of the candida species isolated showed resistance to fluconazole, similar to a study that reported fluconazole resistance in 21% isolates18. Fluconazole resistance is mainly due to past fluconazole (azoles), specifically multiple and long-term use19. Extended-term and repeated antifungals are sometimes required in AIDS patients and are at greater risk of developing an infection with resistant strains. Additionally, resistance in C. albicans is associated with a steady increase in non-albicans species as a causative agent of resistant mucosal Candidiasis, especially in patients with high immunosuppression12. Fluconazole resistance was relatively lower (8.7%) in the patients without H.I.V. infection, and maybe this is because of Non-recurrent Candidiasis and minimal prior exposure to antifungal drugs. The development of resistance to antifungal agents, especially to azoles in the candida albicans and non-albicans species, is an area of concern. This species can expand its resistance repertoire with the development of stable resistance to Azoles, including fluconazole. It is well documented that cross-resistance happens between the antifungal drugs2, and when these resistant strains infect a majority of patients, this will limit our choices for treating Candidiasis in such patients.

Although enough literature has accumulated in the last years regarding the prevalence of vaginal colonization and vulvovaginal Candidiasis in HIV-Negative and HIV-Positive women, the deficit in our knowledge remains, mainly related to the pathophysiology of the disease, as the frequency of vulvovaginal Candidiasis does not increase with the H.I.V. positivity status13. In our study, 28 females who were H.I.V. negative were diagnosed with candida vaginitis as compared to 10 females with H.I.V. coinfection, the frequency of vulvovaginal Candidiasis in H.I.V. positive patients is less as compared to the H.I.V. negative group as other forms of Candidiasis develop, present, and get diagnosed earlier13.

As the number of patients with H.I.V. infection continues to increase in number due to the increase in survival rates, the problem of opportunistic infection also grows in parallel. A few years back, C. albicans was the significant species implicated in Candidiasis in immunocompromised conditions; although it still is, the incidence of Non-albicans Candida and its rise is a matter of concern. Therefore, for the appropriate management of Candida infections, antifungal susceptibility has become an essential tool, especially in the present scenario of increasing resistance.


We would like to acknowledge and thank the National AIDS Control Program (NACO) Ministry of Health and Family Welfare and the Uttar Pradesh State AIDS Control Society (UPSACS) for providing the resources for HIV status screening. We would also like to express our heartfelt thanks to Mr. Sanjay Sharma, Senior Technical Assistant, Mycology Laboratory Department of Microbiology, Jawaharlal Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh, India, for providing his expert technical assistance on methods.

The authors declare that there is no conflict of interest.

All authors designed the experiments. PAK. performed the experiments. PAK and NF, analysed the data. PAK and NF wrote the manuscript. HMK gave his invaluable inputs at all the stages of this work. AA helped in proof-reading and editing the manuscript. MAK, SS did the technical work and helped in editing the manuscript. All authors read and approved the manuscript.


This article does not contain any studies with human participants or animals performed by any of the authors.

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

  1. Khedri S, Santos A, Roudbary M, et al. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. Lett Appl Microbiol. 2018;67(4):392-399.
  2. Mane A, Vidhate P, Kusro C, et al. Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India. Mycoses. 2016;59(2):93-100.
  3. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations. J Clin Microbiol. 2000;38:1563-1568.
  4. Berman J, Krysan DJ. Drug resistance and tolerance in fungi. Nat Rev Microbiol. 2020;18(6):319-331.
  5. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: Treatment issues. Clin Infect Dis. 1998;26(2):259-274.
  6. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS. 1994;8(7):945-950.
  7. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. 2000;30:749-756.
  8. Chander J. Candidiasis. In: Textbook of Medical Mycology. 4th ed. New Delhi: JP Medical Ltd; 2017:401-433.
  9. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. CLSI Document M27- A3. Wayne, PA: Clinical and Laboratory Standards Institute. 2008.
  10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement (M27-S4). Wayne, PA: Clinical and Laboratory Standards Institute. 2012.
  11. Shilpa, Andgi A. Clinical profile of opportunistic infections in HIV seropositive patients attending tertiary centre, Raichur, India. Int J Adv Med. 2018;5(6):1369-1373.
  12. Nagalingeswaran K, Solomon S,Madhivanan P, et al. Correlation between plasma viral load and CD4+T cell count to opportunistic infections in persons with HIV in South India. Int Conf AIDS. 2000;13.
  13. Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci. 2003;57:16-21.
  14. Wadhwa A, Kaur R, Agarwal SK, Jain S, BhallaP. AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India. J Med Microbiol. 2007;56(8):1101-1106.
  15. Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;311(6):354-358.
  16. Lattif AA, Banerjee U, Prasad R, et al. Susceptibility pattern and molecular type of species specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus positive patients. J Clin Microbiol. 2004;42:1260-1262.
  17. Sahand IH, Maza JL, Eraso E, et al. Evaluation of chrom-pal medium for the isolation and identification of candida dubliniensis in primary cultures from the oral cavity. J Med Microbiol. 2009;58(11):1437-1442.
  18. Enwuru CA, Ogunledun A, Idika N, et al. Fluconazole resistant opportunistic oro-pharyngeal candida and non-candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. African Health Sciences. 2008;8(3):142-148.
  19. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995;39:1-8.

Article Metrics

Article View: 1819

Share This Article

© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.